Loading clinical trials...
Loading clinical trials...
A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis
Conditions
Interventions
ELX/TEZ/IVA
IVA
Locations
24
Australia
The Prince Charles Hospital
Chermside, Australia
Alfred Hospital
Melbourne, Australia
Institute for Respiratory Health
Nedlands, Australia
Telethon Kids Institute
Nedlands, Australia
The Royal Children's Hospital
Parkville, Australia
Mater Adult Hospital
South Brisbane, Australia
Start Date
January 14, 2022
Primary Completion Date
December 20, 2022
Completion Date
December 20, 2022
Last Updated
July 11, 2023
NCT02417740
NCT06616857
NCT07108153
NCT02740868
NCT07274631
NCT07303621
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions